ProAxsis obtient un investissement d'environ 1.8 millions de livres sterling
For release on RNS: 07.00, 15 April 2024
NetScientific SA
(« NetScientific » ou la « Société »)
Respiratory disease diagnostics company ProAxsis secures c.£1.8 million investment
NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that its portfolio company ProAxsis Limited (ProAxsis) has successfully closed a c.£1.8 million investment (Investissement).
The Investment was led by the Company's wholly owned venture capital and corporate finance firm, EMV Capital, syndicated from a cohort of private investors. The Investment includes c.£211,000 from new investors, c.£36,000 from the exercise of warrants (Mandats) granted to existing investors in connection with convertible loan notes (CLN), the conversion of the CLNs (and interest thereon) valued in total at c.£455,000, and the conversion of loans from NetScientific valued at c.£776,000. This additional funding is complemented by ongoing non-dilutive funding from, amongst other grants awarded, a recent c.£333,000 grant from Innovate UK.
The new shares issued in connection with the Investment (other than those resulting from the exercise of the Warrants), are preferred shares (Actions privilégiées) with a liquidation preference multiple of 1.1 (Préférence de liquidation). The new shares issued in connection with the exercise of the Warrants are ordinary shares. The two share classes rank pari passu save as regards the Liquidation Preference.
In addition to the Investment, ProAxsis has provided for up to a further £289,000 to be raised on the same terms as the existing new investors in the Preferred Shares (Follow-on Investment).
Following the Investment, the Company's direct stake in ProAxsis is 90.66 per cent, which equates to a post-investment fair value of c.£8.0 million, an increase of c.229 per cent. from the £3.5 million reported as at 30 September 2023. In addition, following the introduction of investors by EMV Capital, the NetScientific capital under advisory with ProAxsis is 8.81% of the fully diluted share capital.
The proceeds of the Investment (and any Follow-on Investment) will, inter alia, support ProAxsis in the development of its Patient Point of Care product range, and its working capital requirements, as well as its endeavours to attract strategic partners.
Dr Ilian Iliev, CEO of NetScientific, and Investor Director of ProAxsis said:
"We welcome this additional funding for ProAxsis. Complemented by the CLNs and Innovate UK grant, these investments demonstrate strong financial support as ProAxsis develops its offering to the respiratory disease market, whilst it explores options for a potential sale to a new strategic owner.
"EMV Capital securing this third party funding is a further example of our capital efficient investment model, allowing ProAxsis to grow without reliance upon the NetScientific balance sheet."
La personne chargée d'organiser la publication de cette annonce au nom de la société est Edward Hooper, directeur juridique et directeur exécutif de la société.
CETTE ANNONCE CONTIENT DES INFORMATIONS PRINCIPALES AUX FINS DE L'ARTICLE 7 DE LA VERSION ROYAUME-UNI DU RÈGLEMENT (UE) N° 596/2014 QUI FAIT PARTIE DU LOI BRITANNIQUE EN VERTU DE LA LOI DE L'UNION EUROPÉENNE (RETRAIT) 2018, TEL QUE MODIFIÉ. LORS DE LA PUBLICATION DE CETTE ANNONCE VIA UN SERVICE D'INFORMATION RÉGLEMENTAIRE, CETTE INFORMATION PRINCIPALE EST MAINTENANT CONSIDÉRÉE COMME ÊTRE DU DOMAINE PUBLIC.
-Prend fin-
NetScientifique
NetScientifique | |
Ilian Iliev, PDG | Via Belvédère Communications |
|
|
Panmure Gordon (UK) Limited (NOMAD et Broker) |
|
Emma Earl / Freddy Crossley / Will Goode / Mark Rogers (Financement d'entreprise) Rupert Dearden (courtage en entreprise) | + 44 (0) 20 7886 2500 |
Belvédère Communications John West / Llewellyn Angus / Lily Pearce |
+ 44 (0) 20 7653 8702 |
À propos de NetScientific
NetScientific plc (AIM : NSCI) est un groupe d'investissement en capital-risque dans les technologies profondes et les sciences de la vie avec un portefeuille international d'entreprises innovantes.
NetScientific identifie, investit et construit des entreprises à forte croissance au Royaume-Uni et à l'international. La société ajoute de la valeur grâce à la gestion proactive de son portefeuille, en progressant vers des points d'inflexion de valeur clés et en générant des retours sur investissement grâce à des événements de liquidité partielle ou totale.
NetScientific se différencie en employant une approche d'investissement efficace en termes de capital, en utilisant judicieusement son bilan et en syndiquant les investissements par l'intermédiaire de sa filiale de capital-risque en propriété exclusive, EMV Capital. Le groupe obtient un mélange de participations directes et de participations portatives dans son portefeuille de sociétés, créant ainsi une structure légère capable de prendre en charge un large portefeuille.
NetScientific a son siège social à Londres, au Royaume-Uni, et est admis à la négociation sur AIM, un marché exploité par la Bourse de Londres.
www.netscientific.net
About ProAxsis
ProAxsis Limited is a global diagnostics company, based in Northern Ireland, with a specific focus on active protease biomarkers. The company currently commercialises activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.
This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months.
In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.
Aside from the provision of assays, ProAxsis provides clinical services at its purpose-built laboratory facility in Belfast and supports pharmaceutical company-sponsored Phase I, II and III clinical trials.
www.proaxsis.com
RNS peut utiliser votre adresse IP pour confirmer le respect des termes et conditions, pour analyser votre interaction avec les informations contenues dans cette communication et pour partager cette analyse de manière anonyme avec d'autres dans le cadre de nos services commerciaux. Pour plus d'informations sur la manière dont RNS et la Bourse de Londres utilisent les données personnelles que vous nous fournissez, veuillez consulter notre Politique de confidentialité.